Innovation Pharmaceuticals Inc. (IPIX)
Innovation Pharmaceuticals Inc.
301 Edgewater Place
Suite 100
Wakefield, MA 01880
United States
978 921 4125
https://www.ipharminc.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 4
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Leo Ehrlich CPA | Chairman, CEO, CFO, Principal Accounting Officer & Secretary | 515.85k | N/D | 1958 |
| Ms. Jane Harness M.S., MP | Senior Vice President of Clinical Sciences & Portfolio Management | 275k | N/D | 1968 |
| Mr. Jim Boeheim | Business Advisor | N/D | N/D | N/D |
Descripción
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Innovation Pharmaceuticals Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
